as informed in news-medical
Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients
Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients
Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen.Fulvestrant is a selective estrogen receptor degrader that targets the function of the hormone receptor so, unlike aromatase inhibitors such as anastrozole, it does not interfere with estrogen levels themselves.The randomized, double-blind, multi-center phase III trial enrolled 462 women with inoperable locally-advanced or metastatic ER-positive, HER-negative breast cancer, who had not received prior hormone therapy.Half the patients (n=230) were randomized to 500mg intramuscular injections of fulvestrant (Days 0, 14, 28, then every 28 days), or to 1mg of anastrozole daily (n=232), and were also allowed one line of chemotherapy.
as well fiercepharma
UDPATED: Novartis' Ibrance challenger cuts breast cancer progression risk by 44%
UDPATED: Novartis' Ibrance challenger cuts breast cancer progression risk by 44%
COPENHAGEN, Denmark--Back in May, Novartis called an early halt to a Phase III study of breast cancer med LEE011--a future rival to Pfizer's Ibrance--because the drug had already shown it could beat a standard treatment at stalling the disease.Saturday, the Swiss drugmaker revealed just now much.The combination of LEE011--also known as ribociclib--and Femara (letrozole) cut the risk of disease progression or death by 44% over solo Femara in women with cancers classified as hormone receptor positive and human epidermal growth factor receptor-2 negative, Novartis said at the ESMO 2016 Congress.The duo regimen also bumped up tumor shrinkage, with more than half of women with measurable disease seeing their tumor size cut by at least 30%.
in like manner buffalonews
WNY breast cancer survivors share the lessons of how to thrive after treatment
WNY breast cancer survivors share the lessons of how to thrive after treatment
Sara Szeglowski began her battle with Stage 2B breast cancer four years ago at age 38, when her son, Finn, was only a year old.She endured a double mastectomy, chemotherapy and radiation, all within the protective reach of a breast care team in Rhode Island, where she lived and worked at the time.When the team told her the heavy lifting was done – that she could start seeing them far less often for follow-up testing – she was terrified."During treatment it feels like you have some control day to day," said Szeglowski, a Lake View native who moved back to Western New York afterward.
as well wusa9
Health Alert: October is breast cancer awareness month
Health Alert: October is breast cancer awareness month
close up of women with cancer awareness ribbons (Photo: dolgachov)Did you know your risk of breast cancer could be influenced by the type of fat your dad eats?New research has found that the female offspring of male rats that ate a diet high in animal fats were more likely to develop breast cancer.If their results are confirmed in human trials, it may pave the way for new interventions to reduce the risk of breast cancer that involve modifying a father's diet prior to conception.Do you want to have a ton of fun and raise money for women's cancer?
No comments:
Post a Comment